Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada
September 21, 2021 18:10 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it has initiated its first commercial...
Medexus Holds Annual and Special Meeting of Shareholders and Announces Election of Board of Directors
September 16, 2021 16:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”) (TSX: MDP) (OTCQX: MEDXF) today held its annual and special meeting of shareholders virtually. At...
Medexus Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 02, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive...
Medexus Pharmaceuticals Reports Financial and Operational Results for First Quarter Fiscal 2022
August 16, 2021 17:30 ET
|
Medexus Pharmaceuticals Inc
Continued strength in unit demand across key product lines Rupall unit demand growth of 44% for the 12 months ending June 30, 2021 Completion of enrollment for IXINITY® Phase 4 clinical...
Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients
August 12, 2021 07:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that is has completed enrollment in its...
Medexus Schedules First Quarter Fiscal 2022 Conference Call
August 10, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at...
Medexus to Present at Canaccord Genuity’s 41st Annual Growth Conference
August 09, 2021 16:15 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it will be presenting at the Canaccord...
Medexus Schedules Webinar to Discuss FDA Complete Response Letter for Treosulfan
August 04, 2021 10:58 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has scheduled a webinar on...
Complete Response Letter Received from FDA for Treosulfan
August 03, 2021 07:45 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today...
Medexus Appoints New Chief Financial Officer
July 19, 2021 07:40 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad as...